Windtree Therapeutics has entered into an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC. Under the terms of the deal, Windtree will receive 20% of any milestone payments, royalties, or similar economic interests, including all global commercial net revenues generated from the cardiovascular assets. In addition, Windtree will be eligible for a $700,000 payment if Seismic completes a financing round of at least $10 million. The agreement also includes the transfer of certain cardiovascular development payables from Windtree to Seismic, relieving Windtree of future funding obligations for the development of these drug candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9616559) on December 23, 2025, and is solely responsible for the information contained therein.